Show simple item record

dc.creatorHollin, IL
dc.creatorDimmock, AEF
dc.creatorBridges, JFP
dc.creatorDanoff, SK
dc.creatorBascom, R
dc.date.accessioned2020-12-16T19:11:47Z
dc.date.available2020-12-16T19:11:47Z
dc.date.issued2019-01-01
dc.identifier.issn1177-889X
dc.identifier.issn1177-889X
dc.identifier.doihttp://dx.doi.org/10.34944/dspace/4580
dc.identifier.otherHY4PB (isidoc)
dc.identifier.other31190761 (pubmed)
dc.identifier.urihttp://hdl.handle.net/20.500.12613/4598
dc.description.abstract© 2019 Hollin et al. Purpose: Rare diseases present challenges for accessing patient populations to conduct surveys. Clinical Data Research Networks (CDRNs) offer an opportunity to overcome those challenges by providing infrastructure for accessing patients and sharing data. This study aims to demonstrate the feasibility of collecting patient preference information for a rare disease in a CDRN, using idiopathic pulmonary fibrosis as proof of concept. Patients and methods: Utilizing a cohort of idiopathic pulmonary fibrosis (IPF) patients across a CDRN, a discrete choice experiment was administered via electronic and paper methods to collect patient preference information about benefits and risks of two therapeutic options. Survey data were augmented with data from electronic health records and patient-reported outcome surveys. Results: Thirty-three patients completed the preference experiment. The amount of choice attributable to a benefit of slowing of decline in lung function was 36%. Improving efficacy in terms of lung function was 2.16 times as important as improving efficacy in terms of shortness of breath. In terms of side effects, decreasing risk of gastrointestinal problems was 2.6 times as important as decreasing risk of sun sensitivity and 2.4 times as important as decreasing risk of liver injury. In terms of benefit-risk trade-offs, improving efficacy in terms of lung function was 1.6 times as important as decreasing risk of gastrointestinal problems. Conclusion: This study used IPF as a proof of concept to demonstrate the feasibility of collecting patient preference information in a CDRN. The network was advantageous to the study of patient preferences. Future research should continue to explore pathways for the collection and use of patient preference information across networks. The power of consolidated collection efforts may lead to the ability to use preference data to inform decision-making at the regional, specialty, or individual encounter level.
dc.format.extent795-804
dc.language.isoen
dc.relation.haspartPatient Preference and Adherence
dc.relation.isreferencedbyInforma UK Limited
dc.rightsCC BY-NC
dc.rights.urihttps://creativecommons.org/licenses/by-nc/3.0/
dc.subjectstated preference methods
dc.subjectdiscrete choice experiment
dc.subjectpatient-centered outcomes research
dc.subjectbenefit-risk trade-off
dc.titleCollecting patient preference information using a clinical data research network: Demonstrating feasibility with idiopathic pulmonary fibrosis
dc.typeArticle
dc.type.genreJournal Article
dc.relation.doi10.2147/PPA.S201632
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
dc.date.updated2020-12-16T19:11:44Z
refterms.dateFOA2020-12-16T19:11:47Z


Files in this item

Thumbnail
Name:
Collecting patient preference ...
Size:
499.6Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

CC BY-NC
Except where otherwise noted, this item's license is described as CC BY-NC